UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

RWD110 Real World Outcomes in Patients with Advanced/Metastatic Solid Tumors Who Are Immuno-Oncology (IO) Naive and Received Second-Line Therapy: Analysis by Tumor Mutational Burden (TMB) Status

Value in health, 2022-12, Vol.25 (12), p.S470-S470

2022

Volltextzugriff (PDF)

EE89 Total Cost of Care and Out-of-Pocket Spending for Medicare Fee-for-Service Beneficiaries with Advanced Melanoma, Advanced Renal Cell Carcinoma, or Advanced Non-Small Cell Lung Cancer

Value in health, 2022-07, Vol.25 (7), p.S352

2022

Volltextzugriff (PDF)

EE268 Temporal Trends in Adverse Event Costs with Nivolumab + Relatlimab Combination Therapy or Nivolumab Monotherapy for Patients with Unresectable or Metastatic Melanoma

Value in health, 2023-06, Vol.26 (6), p.S108-S108

2023

Volltextzugriff (PDF)

1582P Real-world management of immune-related adverse events in the community setting

Annals of oncology, 2022-09, Vol.33, p.S1268-S1269

2022

Volltextzugriff (PDF)

CO59 Matching-Adjusted Indirect Comparison (MAIC) of Nivolumab + Relatlimab (NIVO+RELA) Vs. BRAF/MEK Inhibitors for First-Line Treatment of BRAF-Mutant Advanced/Metastatic Melanoma (AMEL)

Value in health, 2023-12, Vol.26 (12), p.S24-S25

2023

Volltextzugriff (PDF)

Testing of Greenhouse Cladding Materials for Space Environments, Part 2: Laminates

Applied engineering in agriculture, 2018, Vol.34 (3), p.575-580

2018

Volltextzugriff (PDF)

Testing of Greenhouse Cladding Materials for Space Environments

Applied engineering in agriculture, 2011, Vol.27 (3), p.449-456

2011

Volltextzugriff (PDF)

COMPARISON OF MODELS FOR ESTIMATING FLOOD QUANTILES IN NEW HAMPSHIRE AND VERMONT

Journal of the American Water Resources Association, 1999-10, Vol.35 (5), p.1233-1243

1999

Volltextzugriff (PDF)

COMPARISON OF MODELS FOR ESTIMATING FLOOD QUANTILES IN NEW HAMPSHIRE AND VERMONT 1

Journal of the American Water Resources Association, 1999-10, Vol.35 (5), p.1233-1243

1999

Volltextzugriff (PDF)

COMPARISON OF MODELS FOR ESTIMATING FLOOD QUANTILES IN NEW HAMPSHIRE AND VERMONT1

Journal of the American Water Resources Association, 1999-10, Vol.35 (5), p.1233-1243

1999

Volltextzugriff (PDF)

Periodontal Status and Quality of Life: Impact of Fear of Pain and Dental Fear

Pain research & management, 2017-01, Vol.2017 (2017), p.1-9

2017

Volltextzugriff (PDF)

Lattice Boltzmann electrokinetics simulation of nanocapacitors

The Journal of chemical physics, 2019-09, Vol.151 (11)

2019

Volltextzugriff (PDF)

A simple, rapid, and sensitive fluorescence-based method to assess triacylglycerol hydrolase activity

Journal of lipid research, 2021-01, Vol.62, p.100115-100115, Article 100115

2021

Volltextzugriff (PDF)

Circulating Endothelial Microparticles in Diabetes Mellitus

Mediators of Inflammation, 2010-01, Vol.2010 (2010), p.219-226

2010

Volltextzugriff (PDF)

The physics of cement cohesion

Science advances, 2021-08, Vol.7 (32)

2021

Volltextzugriff (PDF)

Abstract P112: A Simple, Rapid, And Sensitive Fluorescence-based Method To Assess Triacylglycerol Hydrolase Activities

Arteriosclerosis, thrombosis, and vascular biology, 2021-09, Vol.41 (Suppl_1)

2021

Volltextzugriff (PDF)

Grassland birds demonstrate delayed response to large‐scale tree removal in central North America

The Journal of applied ecology, 2016-02, Vol.53 (1), p.284-294

2016

Volltextzugriff (PDF)

Complex movement disorders at disease onset in childhood narcolepsy with cataplexy

Brain (London, England : 1878), 2011-12, Vol.134 (12), p.3477-3489

2011

Volltextzugriff (PDF)

Renal salt wasting without cerebral disease: Diagnostic value of urate determinations in hyponatremia

Kidney international, 2007-04, Vol.71 (8), p.822-826

2007

Volltextzugriff (PDF)

Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.9557-9557

2024

Volltextzugriff (PDF)

Laser treatment of 13 benign oral vascular lesions by three different surgical techniques

Medicina oral, patología oral y cirugía bucal, 2013-03, Vol.18 (2), p.e279-e284

2013

Volltextzugriff (PDF)

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

British journal of cancer, 2023-04, Vol.128 (8), p.1503-1513

2023

Volltextzugriff (PDF)

Development of the Synthetic Route to PF-06878031 Part 2: Amide Reduction Route

Organic process research & development, 2024-07, Vol.28 (7), p.2446-2461

2024

Volltextzugriff (PDF)

Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9552-9552

2023

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(63)
Tagungsberichte
(1)

Sprache

Englisch
(63)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

RWD110 Real World Outcomes in Patients with Advanced/Metastatic Solid Tumors Who Are Immuno-Oncology (IO) Naive and Received Second-Line Therapy: Analysis by Tumor Mutational Burden (TMB) Status

EE89 Total Cost of Care and Out-of-Pocket Spending for Medicare Fee-for-Service Beneficiaries with Advanced Melanoma, Advanced Renal Cell Carcinoma, or Advanced Non-Small Cell Lung Cancer

EE268 Temporal Trends in Adverse Event Costs with Nivolumab + Relatlimab Combination Therapy or Nivolumab Monotherapy for Patients with Unresectable or Metastatic Melanoma

1582P Real-world management of immune-related adverse events in the community setting

CO59 Matching-Adjusted Indirect Comparison (MAIC) of Nivolumab + Relatlimab (NIVO+RELA) Vs. BRAF/MEK Inhibitors for First-Line Treatment of BRAF-Mutant Advanced/Metastatic Melanoma (AMEL)

Testing of Greenhouse Cladding Materials for Space Environments, Part 2: Laminates

Testing of Greenhouse Cladding Materials for Space Environments

COMPARISON OF MODELS FOR ESTIMATING FLOOD QUANTILES IN NEW HAMPSHIRE AND VERMONT

COMPARISON OF MODELS FOR ESTIMATING FLOOD QUANTILES IN NEW HAMPSHIRE AND VERMONT 1

COMPARISON OF MODELS FOR ESTIMATING FLOOD QUANTILES IN NEW HAMPSHIRE AND VERMONT1

Periodontal Status and Quality of Life: Impact of Fear of Pain and Dental Fear

Lattice Boltzmann electrokinetics simulation of nanocapacitors

A simple, rapid, and sensitive fluorescence-based method to assess triacylglycerol hydrolase activity

Circulating Endothelial Microparticles in Diabetes Mellitus

The physics of cement cohesion

Abstract P112: A Simple, Rapid, And Sensitive Fluorescence-based Method To Assess Triacylglycerol Hydrolase Activities

Grassland birds demonstrate delayed response to large‐scale tree removal in central North America

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data

Complex movement disorders at disease onset in childhood narcolepsy with cataplexy

Renal salt wasting without cerebral disease: Diagnostic value of urate determinations in hyponatremia

Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC)

Laser treatment of 13 benign oral vascular lesions by three different surgical techniques

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

Development of the Synthetic Route to PF-06878031 Part 2: Amide Reduction Route

Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD)

Suchergebnisse filtern